Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06975722 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

A Phase 2 study of Ulcerative Colitis, sponsored by Sanofi.

Recruiting
Registry status
Phase 2
Development phase
99
Enrollment target
20
Study locations

NCT06975722 is a Phase 2 study of Ulcerative Colitis that is actively recruiting participants, run by Sanofi. The registered enrollment target is 99 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06975722, a Phase 2 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Sanofi.

RECRUITING
Registry status
Phase 2
Development phase
99 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Conditions Studied

Ulcerative Colitis

Interventions

  • DRUG Placebo
  • DRUG SAR442970

Study Locations (20)

Florida

  • Investigational Site Number: 8400024 - Jacksonville
  • Investigational Site Number: 8400030 - Kissimmee
  • Investigational Site Number: 8400003 - Lighthouse PT
  • Investigational Site Number: 8400001 - Miami
  • Investigational Site Number: 8400011 - Miami
  • Investigational Site Number: 8400010 - Palmetto Bay
  • Investigational Site Number: 8400019 - Tampa

California

  • Investigational Site Number: 8400009 - Escondido
  • Investigational Site Number: 8400006 - Lancaster
  • Investigational Site Number: 8400025 - Thousand Oaks

New York

  • Investigational Site Number: 8400021 - New York
  • Investigational Site Number: 8400029 - Queens Village

Georgia

  • Investigational Site Number: 8400018 - Marietta

Iowa

  • Investigational Site Number: 8400005 - Iowa City

Massachusetts

  • Investigational Site Number: 8400017 - Boston

Michigan

  • Investigational Site Number: 8400012 - Wyoming

Missouri

  • Investigational Site Number: 8400014 - St Louis

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2025-07-07
Est. Completion 2029-10-17
Phase Phase 2

Sponsor

Sanofi

713 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06975722

The ClinicalTrials.gov registry entry for NCT06975722 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06975722 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, New York.

Frequently Asked Questions

What is clinical trial NCT06975722 about?

NCT06975722 is a clinical study titled "A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis". This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration ...

What is the current status of trial NCT06975722?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2025-07-07. Estimated completion is 2029-10-17.

What conditions does trial NCT06975722 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

What interventions are being tested in trial NCT06975722?

The interventions under investigation include: Placebo (DRUG), SAR442970 (DRUG).

Who is sponsoring clinical trial NCT06975722?

This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06975722 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ulcerative Colitis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.